CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

By Oskar Hansson, J. Seibyl, E. Stomrud, Henrik Zetterberg, John Q. Trojanowski, T. Bittner, V. Lifke, Veronika Corradini, U. Eichenlaub, R. Batrla and 5 more. Alzheimer's & Dementia, 2018

715 citations recorded by the source corpus.

We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort.

Subfields: Physiology, Psychiatry and Mental health, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0fe93bffb40cb37d48bf8842ac955bb9f063f279

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. Henrik Zetterberg
2. Kaj Blennow
3. Oskar Hansson

In Psychiatry and Mental health

1. Henrik Zetterberg
2. Kaj Blennow
3. Oskar Hansson

Citations in the corpus

• Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021 (2021, neutral): “Because there is strong concordance between CSF biomarkers and amyloid PET, either can be used to confirm Aβ burden (79).”
• Biomarkers for Alzheimer's disease: current status and prospects for the future (2018, methodology): “amyloid (1-42) assay was published (104).”